The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Prevnar 13 was produced by Pfizer.
Osborn (pictured left) has over 13 years’ experience in healthcare research and consulting, with a focus on medical devices over the past seven years.
In phase 2 studies, V114 has been shown to match Pfizer’s Prevnar-13 on the 13 serotypes covered by Pfizer’s vaccine in adults, with the added bonus of tackling ... If approved, Merck’s V114 will be a close competitor of Pfizer's Prevnar-13,
The proportion of household members aged 12 years and above who developed influenza was 1.3% in the Xofluza treatment group compared to 13.2% in the placebo arm.
In NSCLC, KRAS G12C is the most common KRAS mutation, with around 13% of patients with NSCLC in the US carrying this particular mutation. ... Data from the phase 1 trial found that seven (53%) of 13 experienced NSCLC patients with the KRAS G12C mutation
Among 32 patients enrolled in the 13-year, long-term LTF-303 study, 64% of patients treated in the phase 1/2 portion and 90% in the phase 2 portion achieved
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...